Francois Valencony started his career in Chicago, IL for Schneider Electric, supporting several acquisitions and growth projects for the North American and South American divisions until 2000. He then actively participated in the development of a software company (G-F-X) in London, UK, subsequently acquired by Descartes group. François has been working for Institut Mérieux since 2003, leading several transactions within the diagnostic and biotech business areas, including global out-licensing, set-up of Joint Venture and acquisitions.
Operational responsibilities held by François Valencony included the set-up of the first research center of bioMérieux in China (2003) and the management of business development and legal & I.P. department from 2005 to 2009, also management of 10 resources dedicated to the overall management of five vaccine programs in active development, from preclinical to phase 2 stage. Francois is currently President of Mérieux Equity Partners and President of MxD North America. François graduated from HEC Paris and holds a Master Degree from CEMS in Köln, Germany.
CURRENT RESPONSIBILITIES & BOARD POSITION
- President & General Manager, Mérieux Equity Partners
- President of MxD North America LLC
- Currently board member of Lavorel Medicare and board observer of Inscripta Inc.